Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Ga.-based medical technology company, recently received the rights to a new patent for its SoftWave technology portfolio.
The patent, a method of preventing and eliminating biofilms (U.S. Patent No. 7,497,834), involves the use of shock waves to penetrate and disrupt bacterial defenses known as biofilm. The method utilizes SoftWave technology to break apart the protective films and allow healthy cells to flush away bacterial fragments. The treatment is useful in reducing the risk of infection, particularly in surgical patients.
Biofilms represent a huge risk for patients and a challenge for healthcare practitioners. Shock waves are a unique, low cost and consistent technology that minimize risks and allow a patient's own defenses to attack bacteria following treatment.
TRT was founded in 2005 to develop unfocused SoftWave technology in wound care and orthopedics and has since expanded its operations to the urology, cardiology, dental and neurological fields. Research has proven that unfocused SoftWave therapy has a strong regenerative effect on all avascular tissues by stimulating strong biologic responses. The biologic responses include production of growth factors, nitric oxide, and critical gene expressions, which result in angiogenesis and improved blood supply with strong antibacterial properties for treated areas. Conditions that benefit from shock wave treatment include acute and chronic wounds, non-healing bones, ischemic heart tissue, prostatitis and burns.